Taken together, this suggests that KP critically exerts its protective effect in vivo under pathophysiological conditions by activating hepatic KISS1R to downregulate lipid synthesis via AMPK activation as well as increasing β-oxidation, thus attenuating the development of NAFLD. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.